Weak anti-SARS-CoV-2 antibody response is associated with mortality in a Swedish cohort of COVID-19 patients in critical care

• Published in: Critical care (London, England) England), 2020-11, Vol.24 (1), p.639-639, Article 639
• Main Authors: Asif, Sana, Frithiof, Robert, Lipcsey, Miklos, Kristensen, Bjarne, Alving, Kjell, Hultström, Michael
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antibodies; Antibodies, Viral - blood; Antibody Formation - physiology; Antigen-antibody reactions; Betacoronavirus; Cohort Studies; Consent; Coronavirus Infections - blood; Coronavirus Infections - mortality; Coronaviruses; COVID-19; Critical care; Critical Care - trends; Female; Health aspects; Humans; Immune response; Infections; Intensive care; Laboratories; Male; Medical research; Medicin och hälsovetenskap; Middle Aged; Mortality; Mortality - trends; Pandemics; Patient outcomes; Patients; Physiological aspects; Pneumonia, Viral - blood; Pneumonia, Viral - mortality; Prognosis; Research Letter; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Sweden - epidemiology; Viral infections
• ISSN: 1364-8535; 1466-609X; 1466-609X; 1364-8535; 1366-609X
• DOI: 10.1186/s13054-020-03362-y

Studies have confirmed the development of a typical antibody response to an acute viral infection in COVID-19 patients [1]. SEE PDF] To our knowledge, this study provides the earliest evidence that an early and potent antibody response may contribute to infection clearance and improved prognosis in patients critically ill with COVID-19. Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.